Pathophysiology and a Rational Basis of Therapy

Digestive Diseases

Volumn 33, Issue 4, 2015, Pages 508-514

  Gracia Sancho, Jordi ^a   Maeso Díaz, Raquel ^a   Bosch, Jaime ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Chronic liver disease; Hepatic vascular resistance; Portal hypertension

Indexed keywords

ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENDOTHELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUKOTRIENE; MONTELUKAST; NITRIC OXIDE; NORADRENALIN; OBETICHOLIC ACID; PROPRANOLOL; RESVERATROL; SIMVASTATIN; SOMATOSTATIN DERIVATIVE; SORAFENIB; TERUTROBAN; THROMBOXANE A2; VASOPRESSIN; VASOPRESSIN DERIVATIVE; ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL TONE; HUMAN; LIVER CIRRHOSIS; MICROANGIOPATHY; MICROCIRCULATION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION; COMBINATION DRUG THERAPY; COMPLICATION; HYPERTENSION, PORTAL; LIVER; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANGIOGENESIS INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION, PORTAL; LIVER; LIVER CIRRHOSIS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR RESISTANCE; VASODILATION;

EID: 84937418322     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000374099     Document Type: Article

References (63)

1. Tsochatzis EA, Bosch J, Burroughs AK: Liver cirrhosis. Lancet 2014; 383: 1749-1761.
2. Bosch J, Pizcueta P, Feu F, Fernandez M, Garcia-Pagan JC: Pathophysiology of portal hypertension. Gastroenterol Clin North Am 1992; 21: 1-14.
3. Iwakiri Y, Groszmann RJ: The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006; 43:S121-S131.
4. Garcia-Pagan JC, Gracia-Sancho J, Bosch J: Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol 2012; 57: 458-461.
5. Rosselli M, MacNaughtan J, Jalan R, Pinzani M: Beyond scoring: a modern interpretation of disease progression in chronic liver disease. Gut 2013; 62: 1234-1241.
6. Befeler AS, Di Bisceglie AM: Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002; 122: 1609-1619.
7. Pinzani M, Rosselli M, Zuckermann M: Liver cirrhosis. Best Pract Res Clin Gastroenterol 2011; 25: 281-290.
8. Bhathal PS, Grossmann HJ: Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985; 1: 325-329.
9. DeLeve LD: Hepatic microvasculature in liver injury. Semin Liver Dis 2007; 27: 390-400.
10. Pinzani M, Gentilini P: Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin Liver Dis 1999; 19: 397-410.
11. Smedsrod B, Le Couteur D, Ikejima K, Jaeschke H, Kawada N, Naito M, et al: Hepatic sinusoidal cells in health and disease: update from the 14th International Symposium. Liver Int 2009; 29: 490-501.
12. Gracia-Sancho J, Lavina B, Rodriguez-Vilarrupla A, Garcia-Caldero H, Bosch J, Garcia-Pagan JC: Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. J Hepatol 2007; 47: 220-227.
13. Steib CJ, Gerbes AL, Bystron M, op den Winkel M, Hartl J, Roggel F, et al: Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A 2. J Hepatol 2007; 47: 228-238.
14. Pinzani M: Hepatic stellate (ITO) cells-expanding roles for a liver-specific pericyte. J Hepatol 1995; 22: 700-706.
15. Friedman SL: Liver fibrosis-from bench to bedside. J Hepatol 2003; 38(suppl 1):S38-S53.
16. DeLeve LD, Wang X, Guo Y: Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology 2008; 48: 920-930.
17. Nieto N: Oxidative-stress and IL-6 mediate the fibrogenic effects of [corrected] Kupffer cells on stellate cells. Hepatology 2006; 44: 1487-1501.
18. Rockey DC, Weisiger RA: Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 1996; 24: 233-240.
19. Bosch J, Arroyo V, Betriu A, Mas A, Carrilho F, Rivera F, et al: Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 1980; 78: 92-99.
20. Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, et al: Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118: 1149-1156.
21. Graupera M, Garcia-Pagan JC, Abraldes JG, Peralta C, Bragulat M, Corominola H, et al: Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 2003; 37: 172-181.
22. Gracia-Sancho J, Lavina B, Rodriguez-Vilarupla A, Garcia-Caldero H, Fernandez M, Bosch J, et al: Increased oxidative stress in cirrhotic rat livers: a potential mechanism contributing to reduced nitric oxide bioavailability. Hepatology 2008; 47: 1248-1256.
23. Yokoyama Y, Xu H, Kresge N, Keller S, Sarmadi AH, Baveja R, et al: Role of thromboxane A2 in early BDL-induced portal hypertension. Am J Physiol Gastrointest Liver Physiol 2002; 284:G453-G460.
24. Graupera M, March S, Engel P, Rodes J, Bosch J, Garcia-Pagan JC: Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers. Am J Physiol Gastrointest Liver Physiol 2005; 288:G763-G770.
25. Rosado E, Rodriguez-Vilarrupla A, Gracia-Sancho J, Tripathi D, Garcia-Caldero H, Bosch J, et al: Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats. Hepatology 2013; 58: 1424-1435.
26. Gracia-Sancho J, Russo L, Garcia-Caldero H, Garcia-Pagan JC, Garcia-Cardena G, Bosch J: Endothelial expression of transcription factor Kruppel-like factor 2. And its vasoprotective target genes in the normal and cirrhotic rat liver. Gut 2011; 60: 517-524.
27. Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, et al: Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999; 117: 1222-1228.
28. Shah V, Wiest R, Garcia-Cardena G, Cadelina G, Groszmann RJ, Sessa WC: Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. Am J Physiol 1999; 277:G463-G468.
29. Shah V, Cao S, Hendrickson H, Yao J, Katusic ZS: Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in rats. Am J Physiol Gastrointest Liver Physiol 2001; 280:G1209-G1216.
30. Laleman W, Omasta A, van de Casteele M, Zeegers M, Vander E, I, Van LL, et al: A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology 2005; 42: 1382-1390.
31. Matei V, Rodriguez-Vilarrupla A, Deulofeu R, Colomer D, Fernandez M, Bosch J, et al: The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology 2006; 44: 44-52.
32. Liu SL, Premont RT, Kontos CD, Zhu SK, Rockey DC: A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med 2005; 11: 952-958.
33. Gracia-Sancho J, Lavina B, Rodriguez-Vilarupla A, Brandes RP, Fernandez M, Bosch J, et al: Evidence against NADPH oxidase modulating hepatic vascular tone in cirrhosis. Gastroenterology 2007; 133: 959-966.
34. Rosado E, Rodriguez-Vilarrupla A, Gracia-Sancho J, Monclus M, Bosch J, Garcia-Pagan JC: Interaction between NO and COX pathways modulating hepatic endothelial cells from control and cirrhotic rats. J Cell Mol Med 2012; 16: 2461-2470.
35. Groszmann RJ: Hyperdynamic circulation of liver disease 40. Years later: pathophysiology and clinical consequences. Hepatology 1994; 20: 1359-1363.
36. Wiest R, Shah V, Sessa WC, Groszmann RJ: NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 1999; 276:G1043-G1051.
37. Martell M, Coll M, Ezkurdia N, Raurell I, Genesca J: Physiopathology of splanchnic vasodilation in portal hypertension. World J Hepatol 2010; 2: 208-220.
38. Hennenberg M, Biecker E, Trebicka J, Jochem K, Zhou Q, Schmidt M, et al: Defective RhoA/ Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 2006; 130: 838-854.
39. Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodes J, Bosch J: Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol 2005; 43: 98-103.
40. Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia-Pagan JC, Bosch J: Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology 2007; 46: 1208-1217.
41. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M: Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009; 49: 1245-1256.
42. Di Pascoli M, Divi M, Rodriguez-Vilarrupla A, Rosado E, Gracia-Sancho J, Vilaseca M, et al: Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. J Hepatol 2013; 58: 904-910.
43. Guillaume M, Rodriguez-Vilarrupla A, Gracia-Sancho J, Rosado E, Mancini A, Bosch J, et al: Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats. J Hepatol 2013; 58: 240-246.
44. Hsu SJ, Wang SS, Hsin IF, Lee FY, Huang HC, Huo TI, et al: Green tea polyphenol decreases the severity of portosystemic collaterals and mesenteric angiogenesis in rats with liver cirrhosis. Clin Sci (Lond) 2014; 126: 633-644.
45. Trebicka J, Hennenberg M, Odenthal M, Shir K, Klein S, Granzow M, et al: Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 2010; 53: 702-712.
46. Marrone G, Maeso-Diaz R, Garcia-Cardena G, Garcia-Pagan JC, Bosch J, Gracia-Sancho J: KLF2 exerts anti-fibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut 2014; in press: doi: 10.1136/gutjnl-2014-308338.
47. Marrone G, Russo L, Rosado E, Hide D, Garcia-Cardena G, Garcia-Pagan JC, et al: The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol 2013; 58: 98-103.
48. Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, et al: Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 2014; 59: 2286-2298.
49. Steib CJ, Bilzer M, op den Winkel M, Pfeiler S, Hartmann AC, Hennenberg M, et al: Treatment with the leukotriene inhibitor montelukast for 10. Days attenuates portal hypertension in rat liver cirrhosis. Hepatology 2010; 51: 2086-2096.
50. Klein S, van Beuge MM, Granzow M, Beljaars L, Schierwagen R, Kilic S, et al: HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. J Hepatol 2012; 57: 1220-1227.
51. Williams EJ, Benyon RC, Trim N, Hadwin R, Grove BH, Arthur MJ, et al: Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut 2001; 49: 577-583.
52. Hernandez-Guerra M, Garcia-Pagan JC, Turnes J, Bellot P, Deulofeu R, Abraldes JG, et al: Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. Hepatology 2006; 43: 485-491.
53. Yang YY, Lee TY, Huang YT, Chan CC, Yeh YC, Lee FY, et al: Asymmetric dimethylarginine (ADMA) determines the improvement of hepatic endothelial dysfunction by vitamin E in cirrhotic rats. Liver Int 2012; 32: 48-57.
54. De Gottardi A, Berzigotti A, Seijo S, D'Amico M, Thormann W, Abraldes JG, et al: Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial. Am J Clin Nutr 2012; 96: 584-590.
55. Abraldes JG, Rodriguez-Vilarrupla A, Graupera M, Zafra C, Garcia-Caldero H, Garcia-Pagan JC, et al: Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 2007; 46: 1040-1046.
56. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, et al: Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007; 46: 242-253.
57. Abraldes JG, Albillos A, Banares R, Turnes J, Gonzalez R, Garcia-Pagan JC, et al: Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009; 136: 1651-1658.
58. Abraldes JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J, et al: Addition of simvastatin to standard treatment improves survival after variceal bleeding in patients with cirrhosis: a double-blind randomized trial (NCT01095185). J Hepatol 2014; 60:S525.
59. Bosch J, Abraldes JG, Fernandez M, Garcia-Pagan JC: Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol 2010; 53: 558-567.
60. Mejias M, Coch L, Berzigotti A, Garcia-Pras E, Gallego J, Bosch J, et al: Antiangiogenic and antifibrogenic activity of pigment epitheliumderived factor (PEDF) in bile duct-ligated portal hypertensive rats. Gut 2014, Epub ahead of print.
61. Yang L, Kwon J, Popov Y, Gajdos GB, Ordog T, Brekken RA, et al: Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology 2014; 146: 1339-1350.
62. Coch L, Mejias M, Berzigotti A, Garcia-Pras E, Gallego J, Bosch J, et al: Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats. Hepatology 2014; 60: 633-647.
63. D'Amico M, Mejias M, Garcia-Pras E, Abraldes JG, Garcia-Pagan JC, Fernandez M, et al: Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol 2012; 302:G1191-G1198.